Rchr
J-GLOBAL ID:201801019614276496   Update date: Apr. 04, 2021

wada satoshi

ワダ サトシ | wada satoshi
Affiliation and department:
Other affiliations (1):
  • Showa University  School of Medicine Department of Medicine, Division of Oncology 
Homepage URL  (1): https://showa-oncology.jp
Research field  (2): Tumor diagnostics and therapeutics ,  Gastroenterology
Research keywords  (3): tumor immunology ,  腫瘍内科学 ,  がん免疫療法
Papers (58):
  • Ryotaro Ohkuma, Yutaro Kubota, Atsushi Horiike, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Makoto Watanabe, Rie Onoue, Kiyohiro Ando, Junji Tsurutani, et al. The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer. Pancreas. 2021. 50. 2. 167-175
  • Ryotaro Ohkuma, Erica Yada, Shumpei Ishikawa, Daisuke Komura, Yutaro Kubota, Kazuyuki Hamada, Atsushi Horiike, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, et al. High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer. INTERNATIONAL JOURNAL OF ONCOLOGY. 2021. 58. 1. 57-69
  • Kiyohiro Ando, Verna Cazares-Ordonez, Makoto Makishima, Atsushi Yokoyama, Yusuke Suenaga, Hiroki Nagase, Shinichi Kobayashi, Takehiko Kamijo, Tsugumichi Koshinaga, Satoshi Wada. CEP131 Abrogates CHK1 Inhibitor-Induced Replication Defects and Is Associated with Unfavorable Outcome in Neuroblastoma. JOURNAL OF ONCOLOGY. 2020. 2020. 2752417-2752417
  • Satoshi Wada. [Current Status of Biomarkers in the Use of Immune Checkpoint Inhibitors]. Gan to kagaku ryoho. Cancer & chemotherapy. 2020. 47. 9. 1298-1302
  • Kiyohiro Ando, Kazuyuki Hamada, Midori Shida, Ryotaro Ohkuma, Yutaro Kubota, Atsushi Horiike, Hiroto Matsui, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, et al. A high number of PD-L1(+)CD14(+)monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2020
more...
MISC (237):
  • 大熊 遼太朗, 矢田 英理香, 石川 俊平, 河村 大輔, 久保田 祐太郎, 濱田 和幸, 堀池 篤, 安藤 清宏, 鶴谷 純司, 吉村 清, et al. Human epididymis protein 4の発現が膵臓癌における抗癌剤耐性・予後不良に与える影響. 日本癌学会総会記事. 2020. 79回. OJ15-10
  • 安藤 清宏, 大平 美紀, 末永 雄介, 上條 岳彦, 永瀬 浩喜, 小林 真一, 和田 聡. FGFR2の欠失はCHK1阻害剤が誘導する細胞死の感受性を増強する. 日本癌学会総会記事. 2020. 79回. OE16-6
  • 和田 聡. 【がん免疫療法のバイオマーカー探索】免疫チェックポイント阻害剤使用におけるバイオマーカーの検討. 癌と化学療法. 2020. 47. 9. 1298-1302
  • 和田 聡, 玉田 耕治. 【がん免疫療法の最前線】これからの免疫療法の展望 効かないがんに対する戦略. JOHNS. 2020. 36. 4. 487-491
  • 石黒 智之, 堀池 篤, 石田 博雄, 平澤 優弥, 大熊 遼太朗, 松井 洋人, 有泉 裕嗣, 久保田 祐太郎, 濱田 和幸, 和田 聡, et al. ペムブロリズマブ投与後、皮膚症状が先行し、乾癬性関節炎を発症した肺扁平上皮癌の1例. 肺癌. 2020. 60. 2. 137-137
more...
Professional career (1):
  • 医学博士 (群馬大学)
Work history (2):
  • 2018/05 - 現在 Showa University
  • 2018/05 - 現在 showa university clinical diagnostic oncology professor
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page